Inhibition of IL-1 signaling by antisense oligonucleotide-mediated exon skipping of IL-1 receptor accessory protein (IL-1RAcP)

Molecular Therapy Nucleic Acids

Volumn 2, Issue , 2013, Pages e66-

  Yilmaz Eliş, A Seda ^a   Aartsma Rus, Annemieke ^a   T'Hoen, Peter A C ^a   Safdar, Huma ^a   Breukel, Cor ^a   Van Vlijmen, Bart J M ^a   Van Deutekom, Judith ^b   De Kimpe, Sjef ^b   Van Ommen, Gert Jan ^a   Verbeek, J Sjef ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Prosensa BV   (Netherlands)

Author keywords

Antisense oligonucleotide; Exon skipping; Inflammation; Interleukin 1; Soluble IL 1R accessory protein

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN 6; MESSENGER RNA; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; EXON SKIPPING; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA SPLICING; SIGNAL TRANSDUCTION;

EID: 84878861589     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2012.58     Document Type: Article

References (23)

1. Huang, J, Gao, X, Li, S and Cao, Z (1997). Recruitment of IRAK to the interleukin 1 receptor complex requires interleukin 1 receptor accessory protein. Proc Natl Acad Sci USA 94: 12829-12832. (Pubitemid 27518436)
2. Lang, D, Knop, J, Wesche, H, Raffetseder, U, Kurrle, R, Boraschi, D et al. (1998). The type II IL-1 receptor interacts with the IL-1 receptor accessory protein: a novel mechanism of regulation of IL-1 responsiveness. J Immunol 161: 6871-6877. (Pubitemid 28562232)
3. Symons, JA, Young, PR and Duff, GW (1995). Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist. Proc Natl Acad Sci USA 92: 1714-1718.
4. Smeets, RL, Joosten, LA, Arntz, OJ, Bennink, MB, Takahashi, N, Carlsen, H et al. (2005). Soluble interleukin-1 receptor accessory protein ameliorates collagen-induced arthritis by a different mode of action from that of interleukin-1 receptor antagonist. Arthritis Rheum 52: 2202-2211. (Pubitemid 40994343)
5. Burger, D, Chicheportiche, R, Giri, JG and Dayer, JM (1995). The inhibitory activity of human interleukin-1 receptor antagonist is enhanced by type II interleukin-1 soluble receptor and hindered by type I interleukin-1 soluble receptor. J Clin Invest 96: 38-41.
6. Jensen, LE, Muzio, M, Mantovani, A and Whitehead, AS (2000). IL-1 signaling cascade in liver cells and the involvement of a soluble form of the IL-1 receptor accessory protein. J Immunol 164: 5277-5286. (Pubitemid 30305206)
7. Jensen, LE and Whitehead, AS (2003). Expression of alternatively spliced interleukin-1 receptor accessory protein mRNAs is differentially regulated during inflammation and apoptosis. Cell Signal 15: 793-802. (Pubitemid 36627868)
8. Gabay, C, Smith, MF, Eidlen, D and Arend, WP (1997). Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. J Clin Invest 99: 2930-2940. (Pubitemid 27278670)
9. Smith, DE, Hanna, R, Della Friend, Moore, H, Chen, H, Farese, AM et al. (2003). The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type II IL-1 receptor to inhibit IL-1 action. Immunity 18: 87-96. (Pubitemid 36120690)
10. Dinarello, CA (2005). The many worlds of reducing interleukin-1. Arthritis Rheum 52: 1960-1967. (Pubitemid 40994316)
11. Malinowsky, D, Lundkvist, J, Layé, S and Bartfai, T (1998). Interleukin-1 receptor accessory protein interacts with the type II interleukin-1 receptor. FEBS Lett 429: 299-302. (Pubitemid 28300379)
12. Smeets, RL, van de Loo, FA, Joosten, LA, Arntz, OJ, Bennink, MB, Loesberg, WA et al. (2003). Effectiveness of the soluble form of the interleukin-1 receptor accessory protein as an inhibitor of interleukin-1 in collagen-induced arthritis. Arthritis Rheum 48: 2949-2958. (Pubitemid 37280625)
13. Aartsma-Rus, A and van Ommen, GJ (2007). Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA 13: 1609-1624. (Pubitemid 47481669)
14. Kurreck, J. (2003). Antisense technologies Improvement through novel chemical modifications. Eur J Biochem 270: 1628-1644. (Pubitemid 36532522)
15. Kole, R, Krainer, AR and Altman, S (2012). RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 11: 125-140.
16. Aartsma-Rus, A, van Vliet, L, Hirschi, M, Janson, AA, Heemskerk, H, de Winter, CL et al. (2009). Guidelines for antisense oligonucleotide design and insight into splice-modulating mechanisms. Mol Ther 17: 548-553.
17. Mourich, DV and Iversen, PL (2009). Splicing in the immune system: potential targets for therapeutic intervention by antisense-mediated alternative splicing. Curr Opin Mol Ther 11: 124-132.
18. Braasch, DA, Liu, Y and Corey, DR (2002). Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design. Nucleic Acids Res 30: 5160-5167. (Pubitemid 36033034)
19. Vollmer, J, Jepsen, JS, Uhlmann, E, Schetter, C, Jurk, M, Wader, T et al. (2004). Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA). Oligonucleotides 14: 23-31. (Pubitemid 38524632)
20. Raouane, M, Desmaele, D, Urbinati, G and CouvVeur, P (2012). Lipid conjugated oligonucleotides: a useful strategy for delivery. Bioconjugate Chem 23: 1091-1104.
21. Jensen, LE and Whitehead, AS (2004). The 3' untranslated region of the membrane-bound IL-1R accessory protein mRNA confers tissue-specific destabilization. J Immunol 173: 6248-6258. (Pubitemid 39487783)
22. Ko, JK and Ma, J (2005). A rapid and efficient PCR-based mutagenesis method applicable to cell physiology study. Am J Physiol, Cell Physiol 288: C1273-C1278. (Pubitemid 40991064)
23. Greene, AK and Puder, M (2003). Partial hepatectomy in the mouse: technique and perioperative management. J Invest Surg 16: 99-102. (Pubitemid 36609041)